Current Report Filing (8-k)

0001661053 false 12-31 0001661053 2021-09-29 2021-09-29 0001661053 HIJI:CommonStockParValue0.00001PerShareMember 2021-09-29 2021-09-29 0001661053 HIJI:WarrantToPurchaseCommonStockMember 2021-09-29 2021-09-29 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K

 

CURRENT REPORT

Pursuant to Section 13 OR 15(d) of the

Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): September 29, 2021

 

enVVeno Medical Corporation

(Exact name of registrant as specified in its charter)

 

Delaware		001-38325		33-0936180
(State or other jurisdiction		(Commission		(I.R.S. Employer
of incorporation)		File Number)		Identification No.)

 

70 Doppler

Irvine, California 92618

(Address of principal executive offices) (Zip Code)

 

[phone]

(Registrant’s telephone number, including area code)

 

Hancock Jaffe Laboratories Inc.

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

	☐	Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
	☐	Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
	☐	Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
	☐	Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, par value $0.00001 per share		NVNO		The NASDAQ Stock Market LLC
Warrant to Purchase Common Stock		NVNOW		The NASDAQ Stock Market LLC

 

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company ☒

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

 

 

 

 

 

Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year.

 

On October 1, 2021, Hancock Jaffe Laboratories, Inc. (the “Company”) changed its name to “enVVeno Medical Corporation” (the “Name Change”). The Name Change, which was effective as of 12:01 a.m. Eastern time on October 1, 2021 was accomplished pursuant to a Certificate of Amendment (the “Certificate of Amendment”) to the Company’s Fifth Amended and Restated Certificate of Incorporation, as amended, filed with the Secretary of State of Delaware on September 29, 2021. The Company’s common stock and the Company’s class of listed warrants continue to trade on the Nasdaq Capital Market under enVVeno Medical Corporation and the new symbols are “NVNO” and “NVNOW”, respectively. A copy of the Certificate of Amendment is attached as Exhibit 3.1 hereto and incorporated by reference herein.

 

Item 9.01. Financial Statements and Exhibits

 

(d) Exhibits

 

Exhibit		Description
3.1		Certificate of Amendment
104		Cover Page Interactive Data File (embedded within the Inline XBRL document)

 

 

 

SIGNATURE

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

	enVVeno Medical Corporation
Dated: October 1, 2021	/s/ Robert A. Berman
	Robert A. Berman
	Chief Executive Officer